Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodríguez‐Otero, Sergio Giralt, Salomon Manier et al.|New England Journal of Medicine|2023Cited by 695
Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor ActivityJonathan D. Graves, Pamela M. Holland, Jennifer J. Kordich et al.|Cancer Cell|2014Cited by 155
JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)Sham Mailankody, Andrzej Jakubowiak, Myo Htut et al.|Blood|2018Cited by 124